Paper
0
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Authors
Published
Jul 29, 2010
Show more
Save
Tip0
TipSave
Abstract
Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of death among men with metastatic castration-resistant prostate cancer.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.